First results of a quantitative study of DNA adducts of melphalan in the rat by isotope dilution mass spectrometry using capillary liquid chromatography coupled to electrospray tandem mass spectrometry.

Rats were intravenously injected with a single high dose (10 mg/kg) of the alkylating agent melphalan in order to study DNA-adduct formation. Quantitation of a dGuo-melphalan adduct was done by isotope dilution mass spectrometry using capillary liquid chromatography/mass spectrometry (LC/MS) and [15N5]-labeled dGuo-melphalan as internal standard. DNA-adduct levels were studied in bone marrow, liver and kidney. The instrumental detection limit of the method was determined to be 900 fg (S/N 3, pure standard). These first results clearly show a 10 times higher adduct level in bone marrow compared to kidney and a 6 times higher level compared to liver. More experiments will be necessary to gather more information on the pharmacokinetics of melphalan-DNA adducts under in vivo conditions.

[1]  K. Hemminki,et al.  DNA adducts in experimental cancer research , 1986, Journal of Cancer Research and Clinical Oncology.

[2]  A. Van der Linden,et al.  Qualitative study of in vivo melphalan adduct formation in the rat by miniaturized column-switching liquid chromatography coupled with electrospray mass spectrometry. , 2004, Journal of mass spectrometry : JMS.

[3]  U. Loos,et al.  Relevance of the hydrolysis and protein binding of melphalan to the treatment of multiple myeloma , 2004, Cancer Chemotherapy and Pharmacology.

[4]  R. El-Azhary,et al.  Tissue distribution and macromolecular interactions of 14[C-ring] melphalan in the rat , 2004, Cancer Chemotherapy and Pharmacology.

[5]  E. Esmans,et al.  Alkylation of DNA by melphalan: investigation of capillary liquid chromatography-electrospray ionization tandem mass spectrometry in the study of the adducts at the nucleoside level. , 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[6]  P. L. Bergsagel.  Chemotherapy of multiple myeloma: melphalan--40 years old and still going strong. , 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[7]  M. Churchwell,et al.  Quantification of multiple DNA adducts formed through oxidative stress using liquid chromatography and electrospray tandem mass spectrometry. , 2002, Chemical research in toxicology.

[8]  P. Di Mascio,et al.  Development of an on-line liquid chromatography-electrospray tandem mass spectrometry assay to quantitatively determine 1,N(2)-etheno-2'-deoxyguanosine in DNA. , 2002, Chemical research in toxicology.

[9]  P. Vouros,et al.  Analysis and quantification of DNA adducts of 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline in liver of rats by liquid chromatography/electrospray tandem mass spectrometry. , 2002, Chemical research in toxicology.

[10]  K. Hemminki,et al.  Dna adducts, mutations, and cancer 2000. , 2000, Regulatory toxicology and pharmacology : RTP.

[11]  M. Churchwell,et al.  Quantification of etheno-DNA adducts using liquid chromatography, on-line sample processing, and electrospray tandem mass spectrometry. , 2000, Chemical research in toxicology.

[12]  D. Deforce,et al.  Analysis of melphalan adducts of 2'-deoxynucleotides in calf thymus DNA hydrolysates by capillary high-performance liquid chromatography-electrospray tandem mass spectrometry. , 1999, Journal of chromatography. B, Biomedical sciences and applications.

[13]  E. Esmans,et al.  Liquid chromatography–mass spectrometry in nucleoside, nucleotide and modified nucleotide characterization , 1998 .

[14]  L. Povirk,et al.  Specificity and kinetics of interstrand and intrastrand bifunctional alkylation by nitrogen mustards at a G-G-C sequence. , 1997, Nucleic acids research.

[15]  W. Warren,et al.  Products from alkylation of DNA in cells by melphalan: human soft tissue sarcoma cell line RD and Escherichia coli WP2. , 1995, Chemico-biological interactions.

[16]  B. Samuels,et al.  High-dose intravenous melphalan: a review. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  K. Randerath,et al.  32P-postlabeling methods for DNA adduct detection: overview and critical evaluation. , 1994, Drug metabolism reviews.

[18]  K. Hemminki,et al.  DNA adducts, mutations and cancer. , 1993, Carcinogenesis.

[19]  C. Klein,et al.  Methods used for analyses of "environmentally" damaged nucleic acids. , 1993, Journal of chromatography.

[20]  J. Lay,et al.  Mass spectrometry for the analysis of carcinogen-DNA adducts , 1992 .

[21]  M. Kirsch‐Volders,et al.  Comparison of 32P-postlabelling and cytogenetic analysis of human blood treated in vitro with melphalan. , 1992, Mutagenesis.

[22]  B. Nilsson,et al.  Formation and removal of DNA cross-links induced by melphalan and nitrogen mustard in relation to drug-induced cytotoxicity in human melanoma cells. , 1987, Cancer research.

[23]  M. Tilby,et al.  Immunological detection of DNA damage caused by melphalan using monoclonal antibodies. , 1987, Cancer research.

[24]  R. Lewensohn,et al.  Melphalan-induced DNA cross-linking in human melanoma cells and phytohaemagglutinin-stimulated lymphocytes in relation to intracellular drug content and cellular levels of glutathione. , 1987, Anticancer research.

[25]  T. Henne,et al.  Occurrence of second primary malignancies in man--a second look. , 1985, Cancer treatment reviews.